首页> 外文期刊>Experimental Hematology: Official Publication of the International Society for Experimental Hematology >Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells
【24h】

Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells

机译:符合GMP的培养基对人骨髓间充质基质细胞体外扩增的评估

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Mesenchymal stromal cells (MSCs) from human bone marrow serve as a resource for cell based therapies in regenerative medicine. Clinical applications require standardized protocols according to good manufacturing practice (GMP) guidelines. Donor variability as well as the intrinsic heterogeneity of MSC populations must be taken into consideration. The composition of the culture medium is a key factor in successful MSC expansion. The aim of this study was to comparatively assess the efficiency of xeno-free human platelet lysate (HPL)-based cell expansion with two commercially available media-StemPro MSC SFM CTS (for human ex vivo tissue and cell culture processing applications) and MSCGM (non-GMP-compliant, for research only) in an academic setting as the first optimization step toward GMP-compliant manufacturing. We report the feasibility of MSC expansion up to the yielded cell number with all three media. MSCs exhibited the typical fibroblastoid morphology, with distinct differences in cell size depending on the medium. The differentiation capacity and characteristic immunophenotype were confirmed for all MSC populations. Proliferation was highest using StemPro MSC SFM CTS, whereas HPL medium was more cost-effective and its composition could be adjusted individually according to the respective needs. In summary, we present a comprehensive evaluation of GMP-compatible culture media for MSC expansion. Both StemPro and HPL medium proved to be suitable for clinical application and allowed sufficient cell proliferation. Specific differences were observed and should be considered according to the intended use. This study provides a detailed cost analysis and tools that may be helpful for the establishment of GMP-compliant MSC expansion. (C) 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.
机译:来自人骨髓的间充质基质细胞(MSC)用作再生医学中基于细胞的疗法的资源。根据良好生产规范(GMP)指南,临床应用需要标准化协议。必须考虑MSC群体的供体变异性和固有异质性。培养基的组成是成功进行MSC扩增的关键因素。这项研究的目的是使用两种市售的培养基-StemPro MSC SFM CTS(用于人离体组织和细胞培养处理应用)和MSCGM,比较评估不含异种人血小板裂解物(HPL)的细胞扩增的效率。不符合GMP规范(仅用于研究),这是朝着符合GMP规范的制造迈出的第一步。我们报告了在所有三种培养基中,MSC扩展至产生的细胞数的可行性。 MSC表现出典型的成纤维细胞形态,根据培养基的不同,细胞大小也存在明显差异。证实了所有MSC群体的分化能力和特征性免疫表型。使用StemPro MSC SFM CTS的增殖最高,而HPL培养基更具成本效益,可以根据各自的需要单独调整其成分。总而言之,我们对MSC扩展的GMP兼容培养基进行了全面评估。事实证明,StemPro和HPL培养基均适合临床应用,并能使细胞充分增殖。观察到具体差异,应根据预期用途进行考虑。这项研究提供了详细的成本分析和工具,可能有助于建立符合GMP的MSC扩展。 (C)2016 ISEH-国际实验血液学会。由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号